Mutation analysis of factor VIII in Korean patients with severe hemophilia A

被引:7
|
作者
You, Chur-Woo [5 ]
Son, Hee-Sook [5 ]
Kim, Hee Jin [4 ]
Woo, Eui-Jeon [3 ]
Kim, Soon-Ae [2 ]
Baik, Haing-Woon [1 ]
机构
[1] Eulji Univ, Sch Med, Dept Biochem & Mol Biol, Taejon 301832, South Korea
[2] Eulji Univ, Sch Med, Dept Pharmacol, Taejon 301832, South Korea
[3] Korea Res Inst Biosci & Biotechnol, Translat Res Ctr, Taejon, South Korea
[4] Sungkyunkwan Univ, Sch Med, Dept Lab Med, Seoul, South Korea
[5] Eulji Univ, Sch Med, Dept Pediat, Taejon 301832, South Korea
关键词
Severe hemophilia A; Korean; Factor VIII; Mutation; INHIBITOR DEVELOPMENT; INVERSION HOTSPOT; MOLECULAR-BASIS; GENE; IDENTIFICATION; SITE; POLYMORPHISMS; RECOMBINANT; DIAGNOSIS; RESIDUES;
D O I
10.1007/s12185-010-0593-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hemophilia A is an X-linked recessive disorder caused by mutations of the factor VIII gene. The mutation spectrum has been reported in various populations, but not in Koreans. Mutation analysis of the factor VIII gene was performed in 22 unrelated Korean patients with severe hemophilia A. We extracted genomic DNA from their blood, and assessed intron inversions, deletions, and point mutations by direct DNA sequencing. A multiplex ligation-dependent probe amplification gene dosage assay was also performed to identify exon deletions. Disease-causing mutations were identified in all patients, of which four cases were previously unreported. Seven intron 22 inversions, nine point mutations (6 nonsense mutations and 3 missense mutations), and four small rearrangements were identified. One multi-exon deletion and one 5'-donor splicing site mutation were also observed. Four novel mutations (one small deletion, one multiple exon deletion, one missense, and one splice site mutation) were detected, and point mutations were predominant (40.9%), followed by intron 22 inversions (31.8%). Further studies are required in order to establish a solid conclusion regarding the prevalence of various mutations in the Korean population.
引用
收藏
页码:784 / 791
页数:8
相关论文
共 50 条
  • [41] Inhibitors of Factor VIII in Black Patients with Hemophilia
    Viel, Kevin R.
    Ameri, Afshin
    Abshire, Thomas C.
    Iyer, Rathi V.
    Watts, Raymond G.
    Lutcher, Charles
    Channell, Cynthia
    Cole, Shelley A.
    Fernstrom, Karl M.
    Nakaya, Shelley
    Kasper, Carol K.
    Thompson, Arthur R.
    Almasy, Laura
    Howard, Tom E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (16): : 1618 - 1627
  • [42] The prevalence of factor VIII inhibitor in patients with severe hemophilia-A and its clinical characteristics
    Harijadi
    Gatot, Djajadiman
    Akib, Arwin A. P.
    PAEDIATRICA INDONESIANA, 2005, 45 (7-8) : 177 - 181
  • [43] Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A
    Zhang, Y.
    Roberts, J.
    Tortorici, M.
    Veldman, A.
    St Ledger, K.
    Feussner, A.
    Sidhu, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (06) : 1106 - 1114
  • [44] Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
    Chen Zhenping
    Huang Kun
    Li Gang
    Zhen Yingzi
    Wu Xinyi
    Ai Di
    Liu Guoqing
    Li Zekun
    Alfonso Iorio
    Wu Runhui
    儿科学研究(英文), 2021, 05 (01) : 38 - 45
  • [45] Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients
    Abrantes, Joao A.
    Solms, Alexander
    Garmann, Dirk
    Nielsen, Elisabet, I
    Jonsson, Siv
    Karlsson, Mats O.
    HAEMATOLOGICA, 2020, 105 (05) : 1443 - 1453
  • [46] Is it dangerous to treat previously untreated patients with severe hemophilia A with recombinant factor VIII concentrates?
    Drillaud, Nicolas
    Lienhart, Anne
    Babuty, Antoine
    Dargaud, Yesim
    Chamouard, Valerie
    Trossaert, Marc
    Fouassier, Marc
    Rugeri, Lucia
    Sigaud, Marianne
    Lefranc, Carole
    Ternisien, Catherine
    Meunier, Sandrine
    HAEMOPHILIA, 2020, 26 : 67 - 67
  • [47] Genetic Characterization of the Factor VIII Gene in a Cohort of Colombian Patients with Severe Hemophilia A with Inhibitors
    Doncel, Samuel Sarmiento
    Mosquera, Gina Alejandra Diaz
    Pelaez, Ronald Guillermo
    Cortes, Javier Mauricio
    Rico, Carol Agudelo
    Cadavid, Francisco Javier Meza
    Plazas, Nelson Ramirez
    Amar, Ivan Alfredo Perdomo
    Siado, Jorge Enrique Pena
    Rey, Fabian Andres Parrado
    Montano, Cesar Alberto
    Villadiego, Alexys Maza
    HEMATOLOGY REPORTS, 2022, 14 (02) : 149 - 154
  • [48] IMMUNE-COMPLEX ANALYSIS IN PATIENTS WITH SEVERE HEMOPHILIA-A DURING FACTOR-VIII REPLACEMENT THERAPY
    KORHOLZ, D
    WAHN, V
    VONKRIES, R
    FABRY, U
    GOBEL, U
    KLINISCHE PADIATRIE, 1986, 198 (04): : 306 - 311
  • [49] Epidemiology of Factor VIII Inhibitor Development in Patients with Severe Hemophilia A Treated in our Institution
    Tahara, Teppei
    Ishida, Toshiaki
    Nakamura, Sayaka
    Fujiwara, Takahiro
    Tamura, Akihiro
    Yamamoto, Nobuyuki
    Kozaki, Aiko
    Saito, Atsuro
    Kishimoto, Kenji
    Hasegawa, Daiichiro
    Kosaka, Yoshiyuki
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S115 - S115
  • [50] Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
    Chen, Zhenping
    Huang, Kun
    Li, Gang
    Zhen, Yingzi
    Wu, Xinyi
    Ai, Di
    Liu, Guoqing
    Li, Zekun
    Alfonso, Iorio
    Wu, Runhui
    PEDIATRIC INVESTIGATION, 2021, 5 (01) : 38 - 45